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Background: The ongoing pandemic of SARS-COV-2 has already infected more
than eight million people worldwide. The majority of COVID-19 patients either are
asymptomatic or have mild symptoms. Yet, about 15% of the cases experience severe
complications and require intensive care. Factors determining disease severity are not
yet fully characterized.
Aim: Here, we investigated the within-host virus diversity in COVID-19 patients with
different clinical manifestations.
Methods: We compared SARS-COV-2 genetic diversity in 19 mild and 27 severe cases.
Viral RNAwas extracted from nasopharyngeal samples and sequenced using the Illumina
MiSeq platform. This was followed by deep-sequencing analyses of SARS-CoV-2
genomes at both consensus and sub-consensus sequence levels.
Results: Consensus sequences of all viruses were very similar, showing more than
99.8% sequence identity regardless of the disease severity. However, the sub-consensus
analysis revealed significant differences in within-host diversity between mild and severe
cases. Patients with severe symptoms exhibited a significantly (p-value 0.001) higher
number of variants in coding and non-coding regions compared to mild cases. Analysis
also revealed higher prevalence of some variants among severe cases. Most importantly,
severe cases exhibited significantly higher within-host diversity (mean = 13) compared
to mild cases (mean = 6). Further, higher within-host diversity was observed in patients
above the age of 60 compared to the younger age group.
Conclusion: These observations provided evidence that within-host diversity might play
a role in the development of severe disease outcomes in COVID-19 patients; however,
further investigations are required to elucidate this association.
Keywords: SARS-CoV-2, COVID-19 severity, nonsynonymous mutations, virus quasispecies, within-host diversity
INTRODUCTION
Coronaviruses are a group of single-stranded, positive-sense RNA viruses that infect a wide
range of vertebrates (Cui et al., 2019). There are four human coronaviruses that are seasonal
viruses and cause mild upper respiratory tract infections: OC43, 229E, HKU1, and NL63
(Weiss and Navas-Martin, 2005). In the last two decades, nevertheless, there have been two major
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outbreaks of highly pathogenic human coronaviruses that
emerged from zoonotic origins (Amanat and Krammer, 2020).
The first outbreak occurred in 2003 in China due to the
emergence of severe acute respiratory coronavirus (SARS-CoV-
1) from civet cats. The outbreak resulted in more than 9,000
infections and 774 deaths in 37 countries (de Wit et al., 2016).
The second outbreak occurred in 2012 in Saudi Arabia and
was caused by the Middle East respiratory syndrome-related
coronavirus (MERS-CoV). The virus continues to circulate in
camels and has infected around 2,500 people and resulted in 858
deaths after 8 years of its emergence (de Wit et al., 2016). In
December 2019, a third highly pathogenic coronavirus, SARS-
CoV-2, has spread among humans resulting in the ongoing
pandemic and massive socioeconomic losses around the globe.
As of May 2020, the virus has infected more than eight million
people and resulted in more than 380,000 deaths (World Health
Organization, 2020). Generally, more than 85% of patients either
are asymptomatic or show mild manifestations such as fever,
cough, and fatigue. However, around 15% of patients suffer from
life-threatening complications that can lead to death (Chen et al.,
2020). Severe complications might include the development of
acute respiratory distress syndrome (ARDS), severe pneumonia,
and chronic lung damage (Wolfel et al., 2020; Xu et al.,
2020). Several questions remain unanswered regarding the
determinants of disease severity. Current knowledge attributes
variabilities in disease outcomes to host-related factors such
as age and chronic illness, and infection-related factors such
as lymphocytopenia and cytokine storm, rather than variations
in viral genetics (Zhang et al., 2020). Previous studies have
shown that the within-host genetic diversity of RNA viruses may
impact virus virulence (Vignuzzi et al., 2006), immune escape
(Nowak et al., 1991), and drug resistance (Johnson et al., 2008).
Further, within-virus diversity has been found to contribute
to disease severity in some medically important RNA viruses
such as hepatitis C virus (HCV) and human immunodeficiency
virus (Sullivan et al., 2007; Lauring and Andino, 2010; Wu
et al., 2017). The within-host diversity was also reported in
infected patients during SARS-CoV-1 and MERS coronaviruses
outbreaks; however, little is known about their effect on virus
evolution, transmissibility, and pathogenies (Xu et al., 2004;
Lauring and Andino, 2010; Briese et al., 2014; Park et al.,
2016). To date, thousands of SARS-CoV-2 sequences have been
deposited in public databases; yet, we still lack fundamental
information about the within-host diversity of SARS-CoV-2
and its possible role in disease severity. Here, we compared
TABLE 1 | Summary of the main demographic and clinical characteristics of COVID-19 patients included in this study.
Samples Gender Median age Comorbidities Severity score*
(age range) (only severe cases)
F M 0 1 2 >3 0 1 2 3 4
Mild cases 19 3 16 34 (20–54) 14 4 1 0 —
Severe cases 27 6 21 51 (19–72) 9 6 5 7 4 3 6 8 6
*Severity score was calculated using Sofa score (Cardenas-Turanzas et al., 2012).
the SARS-CoV-2 diversity in COVID-19 patients with mild
and severe manifestations and investigate its impact on clinical
disease severity.
METHODS
Study Groups and Sample Collection
Nasopharyngeal swabs were collected from COVID-19 patients
with variable disease outcomes during the period from Mar
13, and Apr 10, 2020. A total of 46 samples were collected
from 19 mild cases and 27 severe cases. Basic demographic
and clinical information of patients is listed in Table 1. Patients
with mild clinical manifestations showed symptoms such as
fever, cough, and malaise. Patients with severe symptoms were
categorized based on the Sofa score system into five categories
(Cardenas-Turanzas et al., 2012). Associated comorbidities were
reported in 23 patients. Most common reported comorbidities
were hypertension (65%), diabetes (60%), cardiovascular diseases
(26%), and asthma (13%). This study was approved by IRB
committees of Hamad Medical Corporation (MRC-01-20-145)
and Qatar University (QU-IRB 1289-EA/20).
Virus Genome Sequencing and Data
Analysis
Viral RNA was extracted directly from viral transport media
using QIAamp Viral RNA Mini kit (Germany, Qiagen),
according to the manufacturer’s instructions. A total of 100
ng of extracted RNA was reverse transcribed with N8 random
hexamers. Second-strand synthesis, PCR amplification, and full
virus genome sequencing were done using CleanPlex SARS-
CoV-2 Research and Surveillance Panels provided by Paragon
Genomics (Shenzhen, China). Indexed libraries were purified
with Agencourt AMPure XP beads (Beckman Coulter, USA),
quantified using Qubit 4.0 Fluorometer (Invitrogen, USA), and
pooled to a final concentration of 8 pM. Pooled libraries were
then loaded in a 300-cycle sequencing cartridge. Sequencing
was performed on an Illumina MiSeq platform, which generated
about six GB of data. The mean count of paired sequencing
reads per sample was 1.5 × 106 (minimum 0.5 × 106 to
maximum 3.5× 106).
The generated sequencing reads were first trimmed to
remove adaptors using the cutadapt software (https://cutadapt.
readthedocs.io/en/stable/). Additional filtration steps also
included the removal of short reads (<40 nucleotides) and
low-quality reads (<30 Phred score). High-quality sequencing
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reads were then aligned to the reference genome (accession
number: MN908947) using Burrows-Wheeler Alignment
(BWA) (Li and Durbin, 2009). Consensus sequences were
constructed after trimming the PCR primer sequences using
fgbio software package (https://github.com/fulcrumgenomics/
fgbio). We were able to generate near-full genomes (from
nucleotide 10 to nucleotide 29,700) from all samples with an
average coverage of 98%. For variant calling, gatk tools were
used for variant detection at both consensus and sub-consensus
levels (https://gatk.broadinstitute.org). Only variants with Phred
scores of more than 35 and depths of more than 100× were
called. For low-frequency variant calling (frequency >10%),
reads were realigned to consensus sequences reconstructed
from each sample. A phylogenetic tree was generated employing
the general-time reversible (GTR+G) nucleotide substitution
model with 1,000 bootstrap replicates and was displayed using
FigTree (version 1.4.4) (Yang, 1994). Lineages were assigned to
sequences based on the lineage nomenclature system proposed
by Rambaut et al. (2020). Statistical analysis was performed using
Prism7 software.
RESULTS
Analysis of SARS-CoV-2 Nucleotide
Variation
Phylogenetic analysis of viruses consensus sequences revealed the
clustering of SARS-CoV-2 viruses into two major lineages: B.1
(n = 14 viruses) and B.2 (n = 32 viruses) lineages (Figure 1).
Of note, there were no differences in the clustering patterns of
viruses from mild and severe cases.
In-depth sequence analysis revealed a total number of 236
variants with frequency >10% in all SARS-CoV-2 genomes (n =
46 samples) with respect to the reference sequence (MN908947).
Overall, the majority (80%) of variants detected in severe cases
were found at the sub-consensus level (frequency <50%). In
contrast, 40% of variants were found at the sub-consensus level
in mild cases (Figure 2A). In both cases, variants were mainly
located in ORF1ab (n = 164; 69%), while 34 (14%) variants were
detected in the spike (S) gene. A limited number of variants
were reported in other coding regions, including nine variants
in ORF3a, three in the envelope (E) gene, four variants in the
matrix (M) gene, 11 variants in the nucleocapsid (N) gene,
and three in ORF10. Additional nine variants were also found





- end of the genome. A total of 59 synonymous and 177
non-synonymous variants were identified in these eight protein-
coding regions (Figure 2A). Notably, the majority of non-
synonymous variants were detected at the sub-consensus level
(frequency <50%) and never reached consensus sequences. This
may suggest that purifying selection eliminates non-synonymous
mutations before they reach the consensus level. Further, most
of the identified non-synonymous variants (152 out of 177) were
detected exclusively in severe cases compared to only 10 unique
non-synonymous variants in mild cases. Similarly, 49 (out of
59) of identified synonymous variants were found exclusively in
severe cases compared to only five specific synonymous variants
FIGURE 1 | Classification of SARS-CoV-2 viruses. Viruses were classified
based on the lineage nomenclature system proposed in Rambaut et al. (2020).
Numbers inside the boxes represent the total number of samples within
each lineage.
in mild cases. Deletions and insertions (indels) represented 18
and 6% of reported non-synonymous variants, respectively, in
severe cases. Comparably, indels accounted for 10 and 8% of
variations in mild cases. Only one multiple nucleotide variant
(MNV; GGG28881-AAC28883) was detected in the N gene
of both groups of patients but with different prevalence (15%
in mild cases vs. 41% in severe cases) (Figure 2B). Further
analysis of sequences at the sub-consensus level showed that
the majority (84%) of variants found in patients with severe
symptoms were rarely seen in more than one patient, while
more than 85% of variants in mild cases were found in multiple
patients (Figure 2C).
At the consensus level (frequency >50%), all sequences were
showing an overall similarity of >99.9% to Wuhan-Hu-1 strain
regardless of disease severity (Figure 3). Only 54 variants (out
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FIGURE 2 | Genomic variations detected in SARS-CoV-2 viruses. (A) Genomic positions and frequencies of variants found in the SARS-CoV-2 genome (55-29640) of
46 patients. The y-axis represents the frequency of variants, and the x-axis represents the genomic position of variants. (B) A tree map presenting types of variants
found in SARS-CoV-2 genomes of mild (green) and severe (red) cases. (C) Colored parts of the circles represent variants seen in more than one patient.
of 236) were found at the consensus level. Of these, 14 variants
were found in both mild and severe cases. Again here, viruses
from severe cases were carrying twice the number of variants
(n = 42 variants) compared to viruses from mild cases (n = 23
variants). Also, only 11 out of 47 indels appeared in the consensus
sequences of some viruses. Eight of which were seen in viruses
from severe cases and three in viruses from mild cases. In both
groups of patients, most of the reported indels were located in
the ORF1ab and were rarely seen in more than one patient.
Then, we compared the presence and prevalence of variants—
at both consensus and sub-consensus levels—in patients with
severe and mild symptoms. To do so, we only included variants
found in more than one patient (n = 39 variants). Notably, 16 of
these variants were detected exclusively in severe cases; however,
none of these variants was seen in more two patients (Figure 4).
In contrast, the non-synonymous variant, 21,575, was the only
variant exclusively found in mild cases but also at a relatively low
prevalence (11%; p-value 0.0007). Variants at positions 19,944
(synonymous; ORF1ab), 11,074 (insertion; ORF1ab), 20,764
(synonymous; ORF1ab), and 28,881–28,883 (MNV; N) were
found in both groups but at significantly higher prevalence (p
< 0.009) among severe cases. Despite the significant differences
between the two groups at the sub-consensus level, a mutation
pattern was more similar at the consensus level. Analyzing
variants at the consensus level revealed only three differentially
prevalent, all non-synonymous, variants betweenmild and severe
cases. Those variants included two S variants: 21,575 and 25,106,
which were found at significantly higher prevalence (p-value
0.0007 and 0.049, respectively) in mild cases, and one N variant:
28,881–28,883, whichwas significantly higher among severe cases
(p-value 0.0003) (Figure 4). Further investigation on the effect of
these variants is important to explain these differences between
patients with variable clinical outcomes.
Analysis of the spike (S) glycoprotein revealed 31 variants
in the S genes of all sequenced viruses at both consensus and
sub-consensus levels. Overall, the majority of S variants were
non-synonymous variants (n = 25) and were mainly detected
at the sub-consensus level (Figure 5A). Also, the majority of
S variants (n = 24 variants) were exclusively detected in
severe cases, compared to only three unique variants in mild
cases (Figure 5A). All reported S variants were sporadically
detected, except for four variants: 23,403 (29% in mild and
48% in severe), 24,099 (6% in severe), 24,453 (23% in mild
and 13% in severe), and 25,106 (11% in mild and 3% in
severe). Interestingly, only one of the sub-consensus variants,
22,757, corresponding to S399P, was found in the receptor-
binding domain (RBD) of S protein. It was detected once among
severe cases.
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FIGURE 3 | Phylogenetic tree of sequenced SARS-CoV-2 viruses (n = 46 samples). Maximum likelihood phylogeny was reconstructed under the general-time
reversible model (GTR) as inferred by model testing. Nucleotide sequence alignment shows mutations found at the consensus level (>50% frequency) with respect to
the reference strain (MN908947).
At the consensus level, only eight variants (out of 31)
were found in all consensus sequences (Figure 5B). Of these,
variants 21,575 (11%) and 21,641 (5%) were found in viruses
from mild cases, while variants 22,323 (3%), 24,099 (7%), and
25,182 (3%) were found in severe cases only. The two groups
of patients shared only one non-synonymous variant, 23,403,
corresponding to amino acid change D614G (Figure 5B). This
mutation, in particular, was seen at the consensus level of
29% mild cases, while it was seen at both consensus and sub-
consensus sequences of 38 and 10% of severe cases, respectively.
None of the consensus mutations was found in the receptor-
binding domain (RBD), which might indicate adaptation to
human receptors.
Analysis of Within-Host Diversity of
SARS-CoV-2
We then compared within-host diversity between mild and
severe COVID-19 cases by assessing the total number of variants
(frequency >10%) detected within each patient. Overall, the
average number of within-host variants ranged from 4 to 10
variants (mean = 6.2; SD 1.9) in mild cases. On the other
hand, the number of within-host variants was significantly higher
(p < 0.0001) in severe cases, ranging from 5 variants to 44
variants (mean = 16.4; SD 9.9) (Figure 6A). In-depth analysis of
within-host variants revealed the dominance of non-synonymous
variants (mean= 11.3; SD 3.2) over synonymous variants (mean
= 5; SD 7.5) in patients with severe symptoms (p < 0.0001). In
contrast, no significant difference was reported in the number of
non-synonymous (mean = 4.3; SD 0.9) and synonymous (mean
= 1.9; SD 1.4) variants in mild cases (Figure 6B). Additionally,
the within-host diversity was more consistent among mild
cases compared to severe cases who showed higher variabilities
(Figures 6A,B). A subset of severe cases exhibited within-host
diversity patterns similar to those with mild symptoms; all were
patients under the age of 60. Within-host diversity in mild
cases was mainly comprised of variants found at the consensus
level (frequency >50%). On average, mild cases were exhibiting
two sub-consensus variants, ranging from 0 to 5 variants per
patient. In contrast, the higher within-host diversity in severe
cases wasmainly due to variants found at the sub-consensus level.
On average, severe cases exhibited 10 sub-consensus variants,
ranging from 0 to 28 variants per patient. Taken together, these
results suggest that SARS-CoV-2 exists as a complex and dynamic
distribution of variants within infected patients, rather than a
single genomic sequence, in particular, among patients with
severe symptoms.
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FIGURE 4 | Comparison of variant prevalence in mild cases (green) and severe cases (red). Colored parts of the circles (on the left) represent variants seen in more
than one patient. Only variants found in more than one patient were used to generate bar charts. Bar charts demonstrate the prevalence of each variant in patients
within each group (severe vs. mild). Bars with darker colors demonstrate variants detected at the consensus sequence level. P-values are indicated as follows:
****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05.
In the next part of within-host diversity analysis, we
investigated the association between within-host diversity and
(i) patient age, (ii) disease severity, and (iii) number of associated
comorbidities (Figure 7). There was a significant relationship
between within-host diversity and age (Wilcoxon p-value 0.001)
(Figure 7A). As expected, more than half of patients (55%) with
severe symptoms were above the age of 50 and 34% were above
the age of 60. None of the patients with mild symptoms, on
the other hand, was above the age of 60. Higher within-host
diversity was reported among severe cases above the age of 60.
Additionally, within-host diversity was also high among severe
cases who were in their 40 s (n = 7 patients) (Figure 7A). Those
seven patients had severity scores of 2 (in 2 cases), 3 (in 4
cases), and 4 (in one case). Considering the severity levels, results
showed an overall higher within-host diversity in severe cases,
classified as having a severity score of “3,” compared to patients
with severity scores of “2” and “1.” However, the average within-
host diversity was less among patients with a severity score of
“4” (Figure 7B). Despite the significant differences in within-host
diversity between mild and severe cases, these differences were
not obviously seen among severe cases with different severity
scores (Figure 7B). Finally, studies on COVID-19 patients
have documented an increased probability of intensive care
admission among patients with comorbidities (Grasselli et al.,
2020; Guan et al., 2020a; Vardavas andNikitara, 2020). Therefore,
we compared within-host diversity between patients with and
without comorbidities and found no significant differences
(Figure 7C). We also assessed the correlation between within-
host diversity and the number of associated comorbidities, but
again, there was no evidence of a correlation between the two
factors (Figures 7D,E). Overall, our observations suggest that
the remarkably high within-host diversity seen in severe cases
might play a role in disease severity; however, the underlying
mechanism is still to be investigated.
DISCUSSION
Despite the unprecedented efforts to sequence the SARS-CoV-2,
the majority of published data report the virus genetic diversity
at the consensus level. This, however, was found to be insufficient
for understanding the evolution, transmission, and pathogenicity
of RNA viruses (Domingo et al., 1985; Holmes and Moya, 2002).
Furthermore, viral quasispecies has previously been reported
in seasonal coronaviruses such as HKU1 and OC43 (Vabret
et al., 2006; Gorse et al., 2017; Woo et al., 2017), as well as
zoonotic coronaviruses such as SARS-CoV-1 and MERS (Xu
et al., 2004; Tang et al., 2006; Borucki et al., 2016). These findings
suggest the existence of coronaviruses as quasispecies within
infected patients, similar to other RNA viruses. Besides, within-
host diversity of some coronaviruses such as OC43 was found to
be associated with acute respiratory illness in infected patients
(Vabret et al., 2006). The correlation between virus quasispecies
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FIGURE 5 | Variants in the SARS-CoV-2 spike glycoprotein. (A) Genomic position and frequency of variants detected in S genes of all viruses. (B) Schematic
representation showing consensus mutations found in mild (green) and severe (red) cases. D614G mutation was found in both mild and severe cases.
FIGURE 6 | Assessment of within-host SARS-CoV-2 diversity. (A) Total number of variants detected in each patient with mild (green) and severe (red) symptoms.
(B) Number of synonymous (S) and non-synonymous (NS) mutations found within each patient of the two groups (mild vs. severe cases). P-values are indicated as
follows: ****p < 0.0001, ***p < 0.001.
and disease pathogenesis has been thoroughly investigated in
HCV and HIV viruses (Farci et al., 2000; Cabot et al., 2001;
Qin et al., 2005; Dampier et al., 2016). Recently, similar studies
have been conducted in other RNA viruses, such as influenza
viruses (Xue et al., 2018). In contrast, the impact of within-
host virus diversity and infection severity has been rarely
reported among coronaviruses. Therefore, we assessed within-
host diversity of SARS-CoV-2 viruses in COVID-19 patients with
variable disease severities.
In accordance with other studies, analysis of viral sequences
at the consensus level revealed high similarities of all viruses
regardless of disease severity (Shen et al., 2020). Nonetheless,
in-depth analysis revealed the presence of sub-consensus variants
in both mild and severe cases but at significantly higher numbers
among severe cases. The existence of viral quasispecies has
been reported, although not frequently, in COVID-19 patients
(Capobianchi et al., 2020; Ceraolo and Giorgi, 2020; Shen et al.,
2020; van Dorp et al., 2020). One of the earliest studies that
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FIGURE 7 | Correlation between within-host variation (number of variants within each patient) and age (A), severity score (B), and number of comorbidities (C).
Patients with mild symptoms are indicated in green while patients with severe symptoms are indicated in red. Shaded circles in (B–E) indicate patients older than
50 years.
were carried in Wuhan during December 2019 also reported the
presence of within-host variants (range from 0 to 51 variants per
patient) in hospitalized COVID-19 patients (Shen et al., 2020).
Similarly, analysis of the first two cases from Lombardy, Italy,
also revealed the presence of virus quasispecies; however, with
limited variation compared to our study (Capobianchi et al.,
2020). The lower number of reported within-host variants in
the latter study is most probably related to the small number of
samples, the different sequencing protocols, and the low coverage
of sequencing reads.
Despite the diversity in SARS-CoV-2 genomes at the sub-
consensus level, we were not able to identify genomic variability
hotspots at the sub-consensus levels. Overall, very few within-
host variants were detected in more than two patients, which
may suggest a narrow transmission bottleneck or purifying
selection of variants. The latter possibility is further supported
by our results, which showed a significantly high number of
non-synonymous variants at the sub-consensus level, none of
which were seen at the consensus level. Similar findings were
also reported in other SARS-CoV-2 studies (Sigal et al., 2018;
Capobianchi et al., 2020; Shen et al., 2020). Still, other research
groups were able to find variability hotspots in SARS-CoV-2
genomes (Ceraolo and Giorgi, 2020; van Dorp et al., 2020).
Considering SARS-CoV-2 consensus sequences, we were able to
identify three major mutations hotspots in both mild and severe
cases: 11,083 and 14,805 in ORF1ab and 26,144 in ORF3a. Of
these, 14,085, in the RNA-dependent RNA polymerase (RdRp)
coding region, was not found to be a variation hotspot in
SARS-CoV-2 sequences deposited in GISAID (https://nextstrain.
org/ncov/global). However, this is not the first study to report
its appearance (Korber et al., 2020; Pachetti et al., 2020).
Additionally, a study that has been carried out by Eskier et al.
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(2020) indicated that C14408T mutation, in RdRp, can increase
the mutation rate in SARS-CoV-2 viruses (Eskier et al., 2020).
Less prevalent hotspots were also reported among patients of
both groups (Figure 4). Of those, variants 14,408 (RdRp), 23,403
(S), and 28,881 (N) were found to be global mutations hotspots
according to GISAID; however, they were predominantly
observed in Europe (Pachetti et al., 2020; Yao et al., 2020).
The spike (S) glycoprotein mediates virus entry into host cells
and is thought to be the major determinant of host tropism
(Fung and Liu, 2019). Further, the S protein is the main target
of neutralizing antibodies and hence is under constant pressure
to mutate (Delmas et al., 1990; Zhang et al., 2004; Yu et al., 2020).
Therefore, we expected to find more mutations in the S gene
compared to other genes; instead, the distribution of variants
was even across the whole genome. Moreover, none of the S
variants—neither at consensus nor at sub-consensus level—was
located in the receptor-binding domain (RBD) or in the epitope
residues of recently identified neutralizing antibodies, CR3022
and 47RD11 (Wang et al., 2020; Yuan et al., 2020). This might
indicate a potential virus adaption to its new host. It also shows
that the virus can be effectively be targeted using these antibodies.
The lack of significant variations in virus genomes at the
consensus level has provided researchers with the reason to
believe that disease severity is mainly determined by host factors
such as age, comorbidities, and the uncontrolled immune
response (Guan et al., 2020b; Spychalski et al., 2020). So far, age
is considered the main determinant of disease severity (Guan
et al., 2020b). Globally, the fatality rate was found to be 1.4%
in infected patients under the age of 60, 4.5% in patients above
60, and reaching up to 13% in patients above the age of 80
(Spychalski et al., 2020; Verity et al., 2020). In our study, 34%
of severe cases belonged to patients above the age of 60, while
none of the mild cases was above the age of 54. Interestingly,
assessing within-host virus diversity among different age
groups has also revealed higher within-host diversity among
patients above the age of 60 and among patients aged between
43 and 49 years. This could be related to the relatively weak
immune systems, especially among elderlies, which may not
be able to efficiently clear the infection, allowing the virus to
replicate to high diversity. These observations suggest that
higher within-host diversity may further contribute to severe
manifestations commonly seen among elderlies. Further, in
accordance to other studies, the number of patients with at
least a single comorbidity was higher among severe cases (62%)
compared to mild cases (29%), with hypertension being the most
common comorbidity (Grasselli et al., 2020; Guan et al., 2020a,b;
Vardavas and Nikitara, 2020). Unlike the age factor, though,
there was no significant association between comorbidities and
within-host diversity. Instead, severe cases exhibited higher
within-host diversity—compared to mild cases—regardless
of the number of associated comorbidities. The uncontrolled
hyperactivation of the immune response has been also shown to
contribute to severemanifestations seen in SARS-Cov-2 infection
(Wu et al., 2009; Feldmann et al., 2020; Mehta et al., 2020). The
overstimulation of the immune response—mainly cytokines—
has also been documented in SARS and MERS patients (Tisoncik
et al., 2012; van den Brand et al., 2015). It is worth noting that the
presence of the genetically diverse quasispecies is also expected
to result in the production of a wide range of antibodies to
encounter virus diversity. Here, we observed significantly higher
levels (p-value < 0.0001) of within-host diversity among severe
cases compared to mild cases. The presence of these variants,
even at frequencies as low as 10%, might trigger immune
response to produce non-specific cytokines or variant-specific
antibodies, resulting in enhanced immune response and severe
clinical outcomes (Huang et al., 2011; Gong et al., 2020).
However, further investigations to confirm the presence of
these quasispecies-specific antibodies is required to support this
hypothesis. Also, the high diversity of the virus could potentially
increase the fitness of the viral population, making it hard to
eradicate (Domingo et al., 2012; Berngruber et al., 2013). So far,
it is unclear whether these within-host variants occurred as a
result of immune pressure, or they triggered a more aggressive
immune response, which would result in different conclusions.
Therefore, additional studies are needed to explore how this may
influence the immune response toward the virus and whether
there is a selection acting on different variants in infected hosts
or during the transmission.
In conclusion, exploring within-host diversity of this newly
emerged virus, SARS-CoV-2, has revealed significant differences
betweenmild and severe cases, particularly among older patients.
Therefore, further investigation on the within-host diversity
role in disease severity is of significance at this stage of the
pandemic and should be considered in future studies. Further
studies should be conducted using a higher number of samples
collected from patients with variable disease severity and at
different age groups to confirm findings of this study on a large
scale. It is also crucial to compare viral quasispecies in patients
of different age groups as well as from different sample types.
This would also help us better understand disease severity and
transmission patterns.
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